Quick Dispatch:
Your hengrui glp-1 $6 Billion GLP-1 Deal Inked Between Hengrui & New U.S. Firm Hercules orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your hengrui glp-1 $6 Billion GLP-1 Deal Inked Between Hengrui & New U.S. Firm Hercules ships.
Need Help?
Questions about hengrui glp-1 $6 Billion GLP-1 Deal Inked Between Hengrui & New U.S. Firm Hercules, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for hengrui glp-1 $6 Billion GLP-1 Deal Inked Between Hengrui & New U.S. Firm Hercules in your area.
Media Centre
25.15
Hengrui Pharma and Kailera Therapeutics announce successful results from Phase 3 obesity trial in China for HRS9531, a dual GLP-1/GIP Receptor Agonist. More Info: https://t.co/sM9pNr09CH $XBI $IBB $XPH $PPH
24.33
Hengrui Pharma's Potential Rival to El Lilly's Zepbound Leads to 18% Weight Loss in Key Study
25.30
GLP-1 drug - Bamboo Works
28.33
Hefty $6 Billion Deal: Hengrui Licenses GLP-1 Portfolio to Hercules
20.93
Kailera, Hengrui to advance oral obesity drug into 2 new trials
22.29
China Hengrui Medicine has registered a Phase III, multicenter, randomized, double-blind clinical trial of the GLP-1R/GIPR dual agonist HRS9531 for the treatment of obesity (NCT06396429; HRS9531-301)
29.14
